Engineered immune cells target tough blood cancers in early trial
NCT ID NCT07300683
First seen Dec 29, 2025 · Last updated Jun 15, 2026 · Updated 27 times
Summary
This early-phase trial tests whether a new type of CAR T-cell therapy, made from a patient's own blood cells, is safe for children and adults with T cell leukemia or lymphoma that has come back or not responded to standard treatments. Participants receive a short course of chemotherapy before the CAR T cells are infused, then stay in the hospital for close monitoring. The study aims to find the right dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University College London Hospitals
RECRUITINGLondon, United Kingdom
Conditions
Explore the condition pages connected to this study.